PT  - JOURNAL ARTICLE
AU  - Butler, Savannah E.
AU  - Crowley, Andrew R.
AU  - Natarajan, Harini
AU  - Xu, Shiwei
AU  - Weiner, Joshua A.
AU  - Lee, Jiwon
AU  - Wieland-Alter, Wendy
AU  - Connor, Ruth I.
AU  - Wright, Peter F.
AU  - Ackerman, Margaret E.
TI  - Features and Functions of Systemic and Mucosal Humoral Immunity Among SARS-CoV-2 Convalescent Individuals
AID  - 10.1101/2020.08.05.20168971
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.08.05.20168971
4099  - http://medrxiv.org/content/early/2020/08/06/2020.08.05.20168971.short
4100  - http://medrxiv.org/content/early/2020/08/06/2020.08.05.20168971.full
AB  - Understanding humoral immune responses to SARS-CoV-2 infection will play a critical role in the development of vaccines and antibody-based interventions. We report systemic and mucosal antibody responses in convalescent individuals who experienced varying disease severity. Robust antibody responses to diverse SARS-CoV-2 antigens and evidence of elevated responses to endemic CoV were observed among convalescent donors. SARS-CoV-2-specific IgA and IgG responses were often negatively correlated, particularly in mucosal samples, suggesting subject-intrinsic biases in isotype switching. Assessment of antibody-mediated effector functions revealed an inverse correlation between systemic and mucosal neutralization activity and site-dependent differences in the isotype of neutralizing antibodies. Serum neutralization correlated with systemic anti-SARS-CoV-2 IgG and IgM response magnitude, while mucosal neutralization was associated with nasal SARS-CoV-2-specific IgA. These findings begin to map how diverse Ab characteristics relate to Ab functions and outcomes of infection, informing public health assessment strategies and vaccine development efforts.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by NIH NCI supplement to 2 P30 CA 023108-41, the BioMT Molecular Tools Core supported by NIGMS COBRE award P20-GM113132, and by DHMC for providing support for collection of initial cohort samples. S.E.B. is supported by NIH NIAID 2T32AI007363.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Dartmouth-Hitchcock Medical Center Committee for the Protection of Human Subjects (Institutional Review Board) reviewed and approved of this study.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData will be made available upon request following peer review and publication in an archival journal.